Chief of Vascular and Endovascular Surgery at Massachusetts General Hospital Joins Nectero Medical Advisory Team

Nectero Medical Inc. (Nectero) announced today that Matthew J. Eagleton, MD, Chief of Vascular and Endovascular Surgery at the Massachusetts General Hospital, has joined the Nectero Medical Advisory Team.

“We are elated to have Dr. Eagleton join the Nectero Medical Advisory Team,” stated Eric Wells, CEO of Telluride Medical Partners, the company that manages Nectero. “Dr. Eagleton is an accomplished vascular surgeon and an international expert on the treatment of complex aortic disease with endovascular therapy, and will be a key member of the Nectero Medical Advisory Team,” stated Wells.
 
Dr. Eagleton is the Chief of Vascular and Endovascular Surgery at the Massachusetts General Hospital and Co-director of the Fireman Vascular Center. Dr. Eagleton received his medical degree (1994) and completed his residency (General Surgery, 2000) from the University of Rochester. He completed specialty training in Vascular Surgery at the University of Michigan in 2002 and obtained advanced training in endovascular procedures at the Cleveland Clinic.

Prior to his current role at Massachusetts General Hospital, Dr. Eagleton was Professor of Surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Vice-Chairman of the Department of Vascular Surgery and Vascular Surgery Director of the Cleveland Clinic Aortic Center.

About Nectero Medical Inc.
Founded in 2017, Nectero is focused on the development of an innovative treatment for Abdominal Aortic Aneurysms (AAA). Nectero’s mission is to address the problem of vascular aneurysms by shifting the treatment paradigm from invasive repair to minimally invasive prevention, starting in the aorta. Nectero’s technology will improve the lives of the millions of patients who are diagnosed with AAA disease and reduce systemic healthcare costs.

TMP Presents at InnoSTARS in Houston, TX

IMG_20180514_122140884.jpg
IMG_20180514_122150827.jpg
IMG_20180514_122159369.jpg

Telluride Medical Partners presented its sleep therapy technology company, Chrona Sleep, Inc., at the InnoSTARS competition in Houston, TX this week. The InnoSTARS Competition is a platform for innovative U.S. companies to compete and connect with investors and partners from China. Those who succeed in their preliminary competition in the U.S. get a chance to travel to China to pitch their business and make international connections while getting real feedback in highly sought-after Chinese innovation hubs. Businesses can meet industry-specific investors and partners with fund sizes larger than $50 million.

TMP was excited to be a part of the competition while having the opportunity to network with investors and partners from China.

Capture Vascular Ranked as Top 10 Cardiovascular Device Company of 2018

c326b1fb-7afd-47c2-8239-1ee397c2a9f2.png

Capture Vascular, Inc. (Capture) has been ranked as a Top 10 Cardiovascular Device Company of 2018 by Medical Tech Outlook Magazine.
 
"We couldn't be more elated to be recognized as one of the Top 10 Cardiovascular Device Companies of 2018," stated Eric Wells, CEO of Capture. "The team has been working hard and 2018 is off to a great start. We continue to generate interest in our commercialized PAD-ATK device. We received the CE Mark in February and continue to receive significant international distribution interest. This has definitely been a very exciting year so far," stated Wells.
 
To add to the momentum, Capture is about to launch its Coronary (CAD) device in September 2018 and anticipates launching its DVT device in Q1 2019.
 
“Dr. Jeffrey Chambers presented Capture's CAD MegaVac Mechanical Thrombectomy System at SCAI 2018 last month in San Diego, CA. Our focus for the balance of 2018 is to get Capture’s devices in the hands of physicians in order to continue to build the data to support the benefits of using the system. We believe that Vascular Surgeons, Interventional Cardiologists, and Interventional Radiologists around the world will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive treatments,” stated Wells.

For the full list of Top Cardiovascular Device Companies as ranked by Medical Tech Outlook Magazine click here.

Venkatesh G. Ramaiah, MD, FACS, Joins Capture Vascular as Medical Advisor

Capture Vascular, Inc. (Capture) is pleased to announce that Venkatesh Ramaiah, MD, FACS, has joined Capture as a Medical Advisor.
 
“We are pleased to have Dr. Ramaiah join the Capture Vascular Medical Advisory Team,” stated Eric Wells, CEO of Capture. “Specializing in endovascular and vascular surgery, Dr. Ramaiah will provide in-depth expertise and guidance related to Capture and its technologies," stated Wells.

Untitled.png

Dr. Ramaiah joined the medical staff of Abrazo Arizona Heart Institute and Hospital in 1999 after a year of private practice in vascular surgery at the Eisenhower Medical Center in Rancho Mirage, California. He received his medical degree (MBBS) and Masters in Surgery (MS) from the University of Bombay in India. He is board-certified in general surgery and completed his surgical training at Episcopal Hospital in Philadelphia. Dr. Ramaiah also completed a fellowship in vascular surgery at the Arizona Heart Institute.

Dr. Ramaiah specializes in endovascular and vascular surgery. He treats conditions such as complications with blood vessels and intervenes to prevent aneurysms and heart attacks. Additionally, Dr. Ramaiah conducts endovascular research at the Arizona Heart Institute. He is currently the medical director of the Arizona Heart Hospital. He is also the director of Peripheral and Endovascular Research at the Arizona Heart Institute, and is the principal investigator in numerous research studies and protocols.

He is actively involved in many prestigious medical groups both nationally and internationally, serving as faculty and director, and has also published extensively in numerous journals and text book chapters.

Capture will be at SCAI 2018 Scientific Sessions April 25-28 in San Diego, CA

SCAI2018_PageBanner.jpg

Capture Vascular, Inc., a Telluride Medical Partners company, will be attending the SCAI 2018 Scientific Sessions conference April 25-28 in San Diego, CA. If you are attending the show we encourage you to stop by Capture Vascular's booth #213 to chat with the team and to attend the Technology Parade Session 1 where Jeff Chambers, MD, FSCAI will present "MegaVac System for Distal Protection and Thrombectomy". If you are interested in setting up a meeting with a Capture Vascular representative please CLICK HERE. More details about the show can be found here.

 

John H. Rundback, MD, Joins Capture Vascular as Medical Advisor

 JOHN H. RUNDBACK, MD, FAHA, FSVMB, FSIR

JOHN H. RUNDBACK, MD, FAHA, FSVMB, FSIR

Capture Vascular, Inc. (Capture) is pleased to announce that renowned interventional radiologist, John H. Rundback, MD, has joined Capture as a Medical Advisor.
 
“We are thrilled to have Dr. Rundback join the Capture Vascular Medical Advisory Team,” stated Eric Wells, CEO of Capture. “With his in-depth experience and expertise in the vascular space, Dr. Rundback will provide significant contribution and expert guidance related to Capture and its technologies,” stated Wells.
 
John H. Rundback, MD, is a renowned interventional radiologist in practice for nearly two decades and is the Director of the Interventional Institute at Holy Name Medical Center. He is board-certified in radiology and holds a Certificate of Added Qualification in Angiography and Interventional Radiology. He has been named as a Top Doctor by Castle Connolly.

Dr. Rundback's research interests include peripheral arterial, carotid and aortic aneurysmal disease, deep venous thrombosis and varicose veins, as well as state-of-the art minimally invasive cancer therapies, and he is the principal investigator on a number of multi-center trials. He has presented at more than 200 conferences and is the program chairman for his own peripheral arterial disease symposium. He has served as an editor and reviewer for peer-reviewed medical journals and published over 100 articles.

At Holy Name, Dr. Rundback serves on the Patient Safety Committee, the Cancer Committee, and the Credentialing Committee. Dr. Rundback is a past member of the Board of Directors of the Society of Interventional Radiology Foundation and Founding Chair for the Foundation's Cooperative Alliance for Interventional Research Clinical Trials Network. Dr. Rundback earned his medical degree from SUNY Downstate Medical Center, after which he completed his internship at St. Vincent's Hospital and Medical Center in New York. He completed his diagnostic radiology residency at Beth Israel Medical Center in New York where he also served as chief resident, and completed his fellowship in interventional radiology at Washington Hospital Center in Washington, DC.

Capture Vascular Receives CE Mark Approval

Capture Vascular, Inc. (Capture), a Telluride Medical Partners company, announced today that it has received CE (Conformité Européenne) marking for its proprietary MegaVac Mechanical Thrombectomy System.
 
“The CE mark is a critical milestone for Capture; the team has been working on its issuance since mid-2017,” stated Eric Wells, CEO of Capture. “We can now launch our sales efforts in Europe, a market that has expressed great interest in Capture’s technology,” stated Wells.
 
Capture is currently in early discussions with a number of European distribution partners, has a few agreements in place, and is working diligently to finalize additional agreements now that the CE mark has been issued.

“We are confident that Vascular Surgeons, Interventional Cardiologists, and Interventional Radiologists throughout Europe will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive peripheral treatments,” stated Wells.

Capture’s proprietary technology includes key features such as centering and securing the occlusion funnel tip position within the vessel and being able to pass other lesion disruptive devices through its lumen.

Founded in 2013, Capture’s proprietary technology includes the MegaVac Catheter with SafeSeal Technology and the ThromboWire Clot Retractor, which makes up the MegaVac Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. For more information about Capture Vascular and its technology please visit www.capturevascular.com.

TMP is a Resident Company at Johnson & Johnson Innovation, JLABS

Telluride Medical Partners announced today that it is now a Resident Company at Johnson & Johnson Innovation, JLABS (JLABS) at the prestigious Texas Medical Center—the world’s largest cancer center—located in Houston, TX (JLABS @ TMC).

“We are thrilled to be part of an elite program dedicated to innovation and the advancement of startup medical companies and technologies,” stated Eric Wells, Founder & CEO of TMP.

JLABS is a 34,000 square-foot life science innovation center located at the Texas Medical Center in Houston, TX. The labs provide a flexible environment for startup companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products, either on their own, or, by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

“Having a presence at JLABS @ TMC will provide Telluride Medical Partners with a concentrated set of unmatched opportunities that can help advance each of our companies and technologies,” stated Wells.